The FDA Clears Larimar Therapeutics' Phase 2 Dose Exploration Trial Of CTI-1601 For Friedreich's Ataxia To Proceed To 50 mg Cohort; Initiation Of Open-label Extension Trial With 25 mg Daily Dosing Expected In Q1 2024; Interim Data Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared Larimar Therapeutics' Phase 2 dose exploration trial of CTI-1601 for Friedreich's Ataxia to proceed to the 50 mg cohort. The initiation of an open-label extension trial with 25 mg daily dosing is expected in Q1 2024, with interim data expected in Q4 2024.
July 25, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Larimar Therapeutics' Phase 2 trial of CTI-1601 has been cleared by the FDA to proceed to the 50 mg cohort. An open-label extension trial is expected to start in Q1 2024.
The FDA's clearance for the next phase of Larimar Therapeutics' trial is a positive development for the company. It allows the company to continue its research and potentially bring a new product to market. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100